Lantheus Holdings, Inc.
Lantheus Holdings, Inc. (Nasdaq: LNTH) develops, manufactures and markets radiopharmaceuticals, imaging agents and related diagnostic and digital products used by healthcare professionals to detect, characterize and monitor disease. Its customers include hospitals, independent imaging centers and government… From the company’s description.
In fiscal 2025, Lantheus Holdings, Inc. reported revenue of $1.54B, up 0.5% from fiscal 2024, and net income of $233.56M. Its operating margin was 20.2%, and operations generated $390.14M in cash. Over the twelve months to Jun 30, 2026, revenue was $1.56B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lantheus Holdings, Inc. does
In the company’s own words
Lantheus Holdings, Inc. (Nasdaq: LNTH) develops, manufactures and markets radiopharmaceuticals, imaging agents and related diagnostic and digital products used by healthcare professionals to detect, characterize and monitor disease. Its customers include hospitals, independent imaging centers and government facilities, primarily in the United States, as well as distributors and partners in international markets. The company organizes its business into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Key products include PYLARIFY, a PET imaging agent for prostate cancer; DEFINITY, an ultrasound-enhancing agent used in echocardiography; and Neuraceq, a PET imaging agent for estimating brain amyloid plaque density in adults evaluated for Alzheimer’s disease. Its other activities include imaging biomarkers, digital applications, licensing and research collaborations, and contract development and manufacturing services through Evergreen. In 2025, Lantheus acquired Life Molecular Imaging, adding Neuraceq and international capabilities, and Evergreen; it sold its SPECT business effective January 1, 2026, including the TechneLite and Cardiolite brands.
Company details
- Sector
- Health Care
- Industry (SIC)
- Chemicals
- Headquarters
- BEDFORD, MA
- Fiscal year end
- December
- CIK
- 1521036
- SIC
- 2835
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lantheus Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lantheus Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Lantheus Holdings, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Lantheus Holdings, Inc.’s debt, $169.69M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.63%, maturing 2027 to 2027.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lantheus Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lantheus Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lantheus Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”